AC Immune SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2026 for AC Immune SA, a foreign private issuer. The report primarily announces the convening of an Extraordinary General Meeting (EGM) scheduled for October 2, 2026, and details proposed changes to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data for the period.
Material Changes
- Board Composition: The Company proposes the election of Tom Graney as a new Board member for a term ending at the 2027 Annual General Meeting.
- Committee Appointment: Subject to election, Mr. Graney is intended to be appointed to the Audit and Finance Committee.
- Board Departure: Carl June has decided to step down from the Board and the Audit and Finance Committee, effective as of the EGM. The departure is not due to any disagreement with the Company.
Guidance, Outlook, and Management Commentary
Management highlights Mr. Graney's extensive background, including over 25 years in biopharma, prior service as CFO at Vertex Pharmaceuticals, Ironwood Pharmaceuticals, and Generation Bio, and a previous tenure on AC Immune's Board from 2016 to 2023. He has contributed to raising over USD 500 million in capital markets. The filing does not provide specific financial guidance, operational outlook, or discuss material risks and contingencies beyond the standard governance transition.
Key Facts for Investor Verification
- Confirm the outcome of the October 2, 2026, Extraordinary General Meeting regarding the election of Tom Graney.
- Verify the effective date of Carl June's departure from the Board and Audit and Finance Committee.
- Review the attached Exhibits 99.1, 99.2, and 99.3 for the full text of the EGM Invitation and Proxy Cards.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial data.